Arrowhead Pharmaceuticals Inc. [ARWR] stock is trading at $28.70, up 3.09%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The ARWR shares have gain 1.92% over the last week, with a monthly amount drifted -7.91%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 25, March 2024, Arrowhead Pharmaceuticals Initiates Expanded Access Program for Plozasiran and Announces Upcoming Presentation of Clinical Data. In a post published today on Yahoo Finance, – Expanded Access Program initiated to make investigational plozasiran available to patients with familial chylomicronemia syndrome.
From an analyst’s perspective:
Arrowhead Pharmaceuticals Inc. [NASDAQ: ARWR] stock has seen the most recent analyst activity on December 04, 2023, when BofA Securities initiated its Buy rating and assigned the stock a price target of $29. Previously, Citigroup started tracking the stock with Neutral rating on September 19, 2023, and set its price target to $33. On July 21, 2023, TD Cowen initiated with a Outperform rating. SVB Securities downgraded its rating to a Market Perform but stick to its price target of $40 on May 12, 2023. SMBC Nikko initiated its recommendation with a Outperform and recommended $80 as its price target on April 26, 2023. SVB Securities upgraded its rating to Outperform for this stock on April 12, 2023, and upped its price target to $35. In a note dated March 21, 2023, Bernstein initiated an Mkt Perform rating and provided a target price of $27 on this stock.
Arrowhead Pharmaceuticals Inc. [ARWR] stock has fluctuated between $20.67 and $42.48 over the past year. Currently, Wall Street analysts expect the stock to reach $63.86 within the next 12 months. Arrowhead Pharmaceuticals Inc. [NASDAQ: ARWR] shares were valued at $28.70 at the most recent close of the market. An investor can expect a potential return of 122.51% based on the average ARWR price forecast.
Analyzing the ARWR fundamentals
Arrowhead Pharmaceuticals Inc. [NASDAQ:ARWR] reported sales of 181.74M for the trailing twelve months, which represents a drop of -94.32%. Gross Profit Margin for this corporation currently stands at 0.92% with Operating Profit Margin at -1.65%, Pretax Profit Margin comes in at -1.67%, and Net Profit Margin reading is -1.63%. To continue investigating profitability, this company’s Return on Assets is posted at -0.47, Equity is -0.95 and Total Capital is -0.53. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.74.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 28.08 points at the first support level, and at 27.45 for the second support level. However, for the 1st resistance point, the stock is sitting at 29.10, and for the 2nd resistance point, it is at 29.49.
Arrowhead Pharmaceuticals Inc. [ARWR] reported earnings per share of -$1.24 for its fiscal quarter that ended on 12/30/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.82/share, meaning a difference of -$0.42 and a surprise factor of -51.20%. By comparison, the stated earnings for the previous quarter ended on 9/29/2023 were -$1.02 per share as compared to estimates of -$0.6 per share, a difference of -$0.42 representing a surprise of -70.00%.
Ratios To Look Out For
For context, Arrowhead Pharmaceuticals Inc.’s Current Ratio is 3.73. Further, the Quick Ratio stands at 3.73, while the Cash Ratio is 0.91. Considering the valuation of this stock, the price to sales ratio is 19.57, the price to book ratio is 19.23.
Transactions by insiders
Recent insider trading involved Lu Hongbo, Director, that happened on Mar 20 ’24 when 1000.0 shares were purchased. Director, Lu Hongbo completed a deal on Mar 19 ’24 to buy 1000.0 shares. Meanwhile, Director Lu Hongbo bought 1000.0 shares on Mar 18 ’24.
